Alliance Healthcare Group Limited Overview
Alliance Healthcare Group is a physician-founded Singapore healthcare platform with roughly S$87m in revenue. It combines six businesses that are usually run separately: a 16-clinic "My Family Clinic" GP chain plus a medical centre; private specialist clinics in orthopaedics, ENT and general surgery; a medical third-party administrator (Alliance Medinet) that manages outpatient and specialist benefits for insurers and corporates across a partner network of more than 2,000 facilities; an HSA-licensed pharmaceutical wholesaler; a home-care and telemedicine arm (Jaga-Me, now 98.4% owned) that supports five public hospitals under the Ministry of Health's MIC@Home programme; and a small institutional health-IT business. Its core thesis is that owning both the payer-side administration and the provider-side delivery lets it steer patient volume through its own network and capture data on utilisation. The company is micro-cap (about S$37m), founder-controlled (about 68%), almost entirely domestic (98% Singapore revenue), thinly traded and uncovered by sell-side research. FY2026 brought a profit inflection.
Company's own description (paraphrased from Annual Report 2025)
The Annual Report 2025 describes Alliance as a trusted medical brand that spans GP and in-house specialist clinics, a corporate health-solutions organisation, a wholesale pharmaceutical company serving the region, and a mobile and home-care provider. It calls itself "physician-led and physician-driven". The report says the company aims to be a next-generation healthcare company that uses technology to deliver cost-effective, personalised services, and that utilisation data helps corporate clients and insurers get better value from their health spending. Its stated vision is to empower people to lead healthy lives through an integrated ecosystem of care. Its stated mission is to be a healthcare innovation company that personalises and simplifies community care delivery. In the FY2025 Chairman's Message, management describes a post-IPO "strategic pivot" away from a traditional brick-and-mortar model towards a digitally enabled platform that links self-owned and partner facilities into a single health ecosystem.
Independent characterisation
On the evidence of its segment accounts, Alliance is best understood as a Singapore managed-care administrator with a captive provider network attached, rather than as a clinic chain.
Managed healthcare solutions: (Alliance Medinet plus in-house corporate clinics) is now the largest segment by revenue (25.4% in FY2026) and by far the largest by profit. It generated S$3.25m pre-tax in FY2026, about 85% of group PBT of S$3.82m. It also carries most of the group's balance sheet: S$70.8m of S$102.8m segment assets, mainly claims receivables offset by claims payables to panel providers.
GP clinic services: (S$20.1m) and specialist care services (S$19.8m) are the provider layer. Both have thin margins, and both are sensitive to doctor retention and start-up costs.
Pharmaceutical services: (S$14.5m) is a wholesale distribution business with an overseas export component. It is shrinking (−10.6% in FY2026).
Mobile and digital health services: (Jaga-Me home care plus HeyAlly telemedicine, S$7.9m) is the main growth investment. It reached EBITDA breakeven in FY2026 for the first time since the COVID-19 boom faded.
Others: (S$2.8m) is now mostly a single institutional IT contract: the clinic management system for the Health Promotion Board's Youth Preventive Service (YHCMS).
Business and revenue model
| Model element | Description | FY2026 revenue (SGD Mn) | Share of group (%) |
|---|---|---|---|
| Fee-for-service medical services | GP and specialist consultations, procedures, health screening, radiology | 39.93 | 45.7 |
| Managed-care / TPA services | Administration fees and managed-care revenue from insurers and corporates; in-house corporate clinic contracts | 22.14 | 25.4 |
| Product sales | Wholesale of medicines, supplements and medical devices | 14.54 | 16.6 |
| Mobile and digital services | Home nursing and medical visits (MIC@Home), telemedicine, health screening | 7.90 | 9.0 |
| Others (incl. project/IT revenue) | YHCMS clinic-management system contract (S$2.7m recognised in FY2026); recognised partly over time | 2.84 | 3.3 |
Source: FY2026 results, Note 4.2 (disaggregation of revenue). In FY2026, S$1.96m of revenue was recognised over time and the balance at a point in time.
There is no subscription or licensing revenue line of material size. The IT contract revenue in "Others" behaves like a project, and SGiMED's software-as-a-service income sits in an associate, so it is not consolidated.
Value-chain position
Alliance sits in the middle of the private outpatient value chain:
Upstream: it procures pharmaceuticals and devices from principals and distributors through Alliance Pharm, which also supplies the group's own clinics.
Midstream: it delivers primary, specialist, home and tele-care through owned facilities, and contracts a panel of more than 2,000 third-party facilities (FY2026 commentary). Those include GP clinics, screening centres, specialist and TCM clinics, labs, imaging centres, a private hospital and home-care providers.
Payer interface: through Alliance Medinet it administers claims for insurers and employers, steering visits into the network at pre-agreed rates. Ecosystem visits were about 1.25m in FY2024, more than 1.45m in FY2025 and about 1.55m in FY2026 (FY2026 results, commentary).
Customer types and end-markets
| Customer type | Segment(s) served | Evidence |
|---|---|---|
| Insurers | Managed healthcare | Eight insurer arrangements at IPO (2019). Named partners over time include Great Eastern, AXA (now HSBC Life), QBE, Aviva (now Singlife), Cigna Europe and EQ Insurance (AR2025 milestones; SGX announcement 31 Jul 2019) |
| Corporate employers | Managed healthcare, GP, digital | More than 2,000 corporations served at IPO (The Edge, 24 May 2019). In-house corporate clinics for SMRT, GlobalFoundries and Marina Bay Sands (AR2025 clinic list) |
| Public hospitals / health clusters | Mobile and digital, managed healthcare | MIC@Home partner for five government-restructured hospitals (FY2026 commentary); NUHS@Home external nursing contract (SGX, 8 Aug 2024) |
| Government agencies | Others | Health Promotion Board YHCMS contract (FY2024 to FY2026 results) |
| Individual patients | GP, specialist, digital | 16 My Family Clinic GP outlets, Alliance Medical Centre, specialist clinics, HeyAlly app |
| Hospitals, pharmacies, clinics, drug manufacturers (Singapore and overseas) | Pharmaceutical | AR2025 Sustainability Report, "Our Business" |
Strategy
Stated strategic themes (paraphrased from AR2025 Chairman's Message and FY2026 commentary)
-
Platform pivot. The company is moving from brick-and-mortar clinics to a digitally enabled platform connecting self-owned and partner facilities into one health ecosystem for corporates, employees and individuals.
-
Ecosystem expansion. It aims to deepen a seamless care journey from preventive care through chronic disease management, specialist treatment and post-hospital care at home, with the goal of better care at lower cost and greater access.
-
Payer-provider integration. Through Alliance Medinet, it works with insurers, employers and providers to deliver care at competitive, predictable prices (FY2026 commentary).
-
Home and hospital-at-home care. It is backing Jaga-Me's growth after taking ownership to 98.4%.
-
Institutional health IT. It will build on YHCMS delivery to pursue more public-sector healthcare technology work.
-
AI and productivity. It is investing in AI and technology to raise productivity, generate data insights and develop new business models (FY2026 commentary).
-
Portfolio optimisation. It plans disciplined execution, including rationalising or repositioning businesses where appropriate (FY2026 commentary). The Evoque exit is the first visible application.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Type | Status / target |
|---|---|---|---|
| Second Elite Orthopaedics clinic (Gleneagles) | May 2025 | New clinic | Contributing in FY2026 |
| Breast and General Surgery clinic (51% JV with Dr Goo Tiong Thye) | Inc. Feb 2025; opened Sep 2025 | New specialty | Contributing in FY2026 |
| Farrer Park Hospital strategic partnership plus Home Recovery Programme | Listed in AR2025 milestones | Payer-provider partnership | Ongoing |
| Jaga-Me NUH palliative care MOU | Listed in AR2025 milestones; non-binding | Partnership | No material FY financial impact expected |
| YHCMS Phases 1–2 delivery | FY2025–FY2026 | Institutional IT | Phase 2 completed about seven months early |
| Jaga-Me consolidation to 98.4% | 30 Jun 2026 | Ownership | Completed |
| Evoque wind-down | Board resolution FY2026; ceased 31 Jul 2026 | Divestment / closure | In progress |
| Share buyback | FY2026 | Capital return | 950,200 shares for S$144,029 |
| Dividend reinstatement and increase | Aug 2025, Aug 2026 | Capital return | 0.10 cents (FY2025), then 0.52 cents proposed (FY2026) |
| Quality management, HR and accounting systems | FY2026 | Internal digitalisation | Commissioned |
| Climate transition plan | Disclosed FY2024–FY2025 | ESG | Cut Scope 2 emissions 25% by FY2035 vs FY2023 |
Medium-term financial targets
Not publicly disclosed. The company states that it has not previously given any forecast or prospect statement (FY2026 results, Item 3). It provides no revenue, margin or return targets. The dividend payout of 29.8% for FY2026 and 30% for FY2023 suggests an informal policy of about 30%, but no formal dividend policy was identified.
Products & Services
Prices and pricing models are not publicly disclosed unless noted. Launch years come from AR2025 and the results filings.
GP clinic services
| Offering | Description / capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| My Family Clinic (Anchorvale) | GP clinic, Blk 326A Anchorvale Rd | Residents; insured and corporate members | — | AR2025 clinic list |
| My Family Clinic (Angsana Breeze @ Yishun) | GP clinic, Blk 507 Yishun Ave 4 | As above | — | Group raised its stake in FY2024 for S$0.53m |
| My Family Clinic (Choa Chu Kang) | GP clinic, Sunshine Place | As above | 1,999 | AR2025 |
| My Family Clinic (Clementi) | GP clinic, Casa Clementi | As above | — | — |
| My Family Clinic (Clementi 325) | GP clinic, Blk 325 Clementi Ave 5 | As above | Acquired as Lee Clinic, 2012–2018 band | Goodwill S$596,071 |
| My Family Clinic (Hougang Central) | GP clinic, Blk 804 Hougang Central | As above | — | Goodwill S$780,000 |
| My Family Clinic (Pioneer) | GP clinic, Pioneer Mall | As above | — | — |
| My Family Clinic (Punggol Central) | GP clinic, Blk 301 Punggol Central | As above | — | — |
| My Family Clinic (Rivervale) | GP clinic, Rivervale Mall | As above | — | — |
| My Family Clinic (Segar) | GP clinic, Blk 485 Segar Rd | As above | — | — |
| My Family Clinic (Senja) | GP clinic, Senja Grand | As above | — | — |
| My Family Clinic (St George) | GP clinic, 2 St George's Rd | As above | Acquired, 2012–2018 band | — |
| My Family Clinic (Tanglin Halt) | GP clinic, Blk 40 Margaret Drive | As above | 1994 (first clinic) | — |
| My Family Clinic (Toa Payoh Central) | GP clinic, Blk 79D Toa Payoh Central | As above | — | — |
| My Family Clinic (Woodlands) | GP clinic, Woodlands Mart | As above | 1,999 | — |
| My Family Clinic (Woodlands Glen) | GP clinic, Blk 573 Woodlands Dr 16 | As above | — | — |
| Alliance Medical Centre (Dhoby) | One-stop centre at Dhoby Ghaut MRT: executive health screening (including exercise stress echocardiogram), GP primary-care hub, chronic disease management programmes, diabetic retinal photography | Corporate clients; commuters; chronic patients | Jan 2024 | Supports the Alliance Chronic Care programme (FY2024 commentary) |
| Alliance Radiology | Digital X-ray, mammography, ultrasound, DEXA, AI-driven echocardiography | Screening and referral patients | Jan 2024 | Housed in the Dhoby centre |
| Healthier SG participation | Enrolment of residents with a family doctor under MOH's Healthier SG programme | Singapore residents | FY2023 onwards | Cited as a GP growth driver in FY2025 and FY2026 |
Specialist care services
| Offering | Specialty / location | Status at Oct 2026 | Notes |
|---|---|---|---|
| Elite Orthopaedics (Mount Elizabeth) | Orthopaedics, Mount Elizabeth Medical Centre #12-10 | Operating | First orthopaedic clinic, 2012–2018 band |
| Elite Orthopaedics (Farrer Park) | Orthopaedics, Farrer Park Hospital, Connexion #10-04 | Operating | AR2025 list |
| Elite Orthopaedics (Gleneagles) | Orthopaedics, Gleneagles Medical Centre #07-09 | Operating | Opened May 2025 |
| My ENT Specialist (Novena) | ENT, Mount Elizabeth Novena Specialist Centre | Operating | Medical director: Executive Director Dr Paul Mok |
| My ENT Specialist (Farrer Park) | ENT, Farrer Park Hospital | Operating | AR2025 list |
| Alliance Specialist Group (Breast and General Surgery) | Breast and general surgery, Gleneagles Medical Centre #03-10; 51% owned, 49% held by Dr Goo Tiong Thye | Operating | Opened Sep 2025 |
| Ho Kok Sun Colorectal | Colorectal surgery, Mount Elizabeth Medical Centre | Ceased 1 Jul 2026 | Management agreement not renewed by the principal doctor |
| Lim Jit Fong Colorectal Centre | Colorectal surgery, Gleneagles Medical Centre | Ceased 1 Jul 2026 | As above |
| Evoque Medical Aesthetics | Lasers, fillers, skin boosters, body contouring; Dhoby Ghaut; 60% owned | Ceased 31 Jul 2026 | Opened Dec 2023; continuing operating losses |
Managed healthcare solutions
| Offering | Description | Customer |
|---|---|---|
| Alliance Medinet TPA / network administration | Outpatient, specialist and inpatient benefits administration; pre-agreed facility rates with a network of more than 2,000 providers (FY2026) | Insurers; employers |
| MediNet platform | Proprietary claims and network-administration system | Internal and partners |
| SIMS (Specialist Inpatient Management System) | Proprietary hospital-claims management system for insurers | Insurers |
| Specialist Appointment Request System | Specialist referral and booking | Members; insurers |
| Alliance iCare app | Member-facing mobile application | Insured and corporate members |
| Cashless arrangements with public hospitals | Cashless SOC and specialist services for insured members at SingHealth, KTPH, TTSH and NUHS | Insurers' policyholders |
| Corporate clinics (My Corporate Clinic) | SMRT Medical Clinic @ Woodlands Depot; My Corporate Clinic @ GlobalFoundries; MBS-Alliance In-house Clinic (Marina Bay Sands) | Large employers |
| Alliance Chronic Care programme | Corporate chronic disease management anchored at the Dhoby centre | Employers |
| Farrer Park Hospital partnership | Pre-agreed, more predictable facility fees for members | Insurers; employers |
| Alliance Medinet (M) Sdn Bhd | Malaysian TPA subsidiary (scale not disclosed) | Malaysian clients |
Pharmaceutical services
| Offering | Description | Customer |
|---|---|---|
| Alliance Pharm wholesale | HSA-licensed wholesaler and importer of therapeutic products, controlled drugs and medical devices; licensed exporter of controlled and psychotropic drugs; quality system aligned to HSA Good Distribution Practice | Clinics, hospitals, pharmacies, drug manufacturers in Singapore and overseas |
| Internal supply | Group procurement for GP, specialist and home-care operations | Group entities |
| Pharmaceutical logistics services | Cited as a higher-margin contributor in FY2025 | Third parties |
| Alliance Pharm (HK) | Sourcing, supply and distribution of pharmaceuticals and devices; incorporated Feb 2024 | Regional customers |
Mobile and digital health services
| Offering | Description | Customer |
|---|---|---|
| Jaga-Me home care | Proprietary web platform for booking home nursing, doctor and therapy visits | Patients; hospitals |
| MIC@Home | Hospital-level care at home for five restructured hospitals (FY2026 commentary). National University Health System and Sengkang General Hospital are named (AR2025) | Public hospitals |
| NUHS@Home external nursing | Contract announced 8 Aug 2024 | NUHS |
| Home Recovery Programme | Post-discharge home recovery with Farrer Park Hospital | Private hospital patients |
| Jaga-Partner Portal (JPP) | Referral and care-instruction portal whitelisted by MIC@Home hospital partners | Hospitals |
| Palliative and supportive care | Non-binding MOU with National University Hospital (exact date not confirmed in sources reviewed; listed among recent milestones in AR2025) | Terminally ill patients |
| HeyAlly app / AllyCare programme | Acute and chronic teleconsultation, second opinions, same-day medication delivery for consults before 10 pm | Individuals; corporate members |
| HeyAlly modules | AllyStore (health products), PayAlly (rewards points), AllyTele (video consults), digital queue ticket, AllyNews, appointments, clinic locator | Consumers |
| Onsite health screening | Corporate screening events | Employers |
Others / health IT
| Offering | Description | Customer |
|---|---|---|
| YHCMS | Supply, customisation and maintenance of a clinic-management system for HPB's Youth Preventive Service Division; tender won with SGiMED; Phases 1 and 2 delivered | Health Promotion Board |
| Ally E-Services | Remote queue, e-appointment, e-payment and teleconsultation tools for MFC and private clinics, built with SGiMED | Private clinics |
| Hummingbird CMS (associate, 30%) | SGiMED's cloud clinic-management and EMR software | Private clinics |
Financial Narrative
All figures are in S$m unless stated. Sources: FY2022 press release; FY2024, FY2025 and FY2026 results; AR2025 Financial Highlights (EBITDA, owners' equity); StockAnalysis/S&P for FY2022 balance-sheet and cash-flow items not otherwise available. The company reports expenses by nature, so it does not report gross profit.
Income statement
Notes:
EBIT: is EBITDA less depreciation and amortisation. It is an analyst derivation. FY2022 D&A of S$2.80m is from S&P data.
FY2022 PBT and net profit: are rounded figures from the FY2022 press release.
FY2022 EPS: is derived as S$3.112m divided by about 206.7m shares; the reported figure was not located.
Basic and diluted EPS are identical: in every year because there are no convertible instruments.
FY2026 dividend: is a proposal subject to the 27 Oct 2026 AGM.
Margins (%)
Gross profit. This is not reported by the company. A third-party derivation by S&P Global (via StockAnalysis), which classifies part of the operating cost as "cost of revenue", gives gross profit of S$9.70m (FY2022), S$8.43m (FY2023), S$9.79m (FY2024) and S$13.26m (FY2025), and S$15.14m on a trailing-twelve-month basis to December 2025. An FY2026 figure was not available. These derived numbers are not comparable to company disclosures and should be treated as indicative only.
Revenue CAGR. FY2022 to FY2026 (4 years): 12.4%. FY2021 (S$46.42m) to FY2026 (5 years): 13.5%. Both are analyst calculations.
Cost structure
Employee benefits include fees paid to non-employee locum doctors and nurses and to contracted specialists. In FY2026, S$6.12m of professional fees were paid to related parties: entities in which subsidiary directors have interests (FY2026 results, Note 6.2).
Commentary on the income statement. The five-year arc has three phases.
-
COVID windfall and unwind (FY2022–FY2024). FY2022 margins (EBITDA 14.7%, net 5.7%) were flattered by Jaga-Me's COVID-19 swab and vaccination work. After that work ended, and as GP COVID subsidies stopped in April 2023, EBITDA fell to S$5.0m in FY2024.
-
Investment drag (FY2024–FY2025). At the same time, the group opened a medical centre, an aesthetics clinic, a pharmaceutical warehouse and corporate clinics. D&A rose 85% from FY2023 to FY2025 and finance costs doubled. FY2024 PBT bottomed at S$24k.
-
Operating leverage (FY2026). Revenue grew 13.3%, but consumables rose only 0.5% because lower-margin pharmaceutical volume fell away. Finance costs fell 29.6% and EBITDA rose 41.5%. PBT more than tripled to S$3.8m despite a S$1.1m operating loss at Evoque.
Staff costs rising faster than revenue (now 58% of sales) are the main structural margin risk, and management names manpower inflation explicitly in its outlook.
Balance sheet (as at 30 June)
Notes:
FY2022 balance-sheet lines: are from S&P (StockAnalysis), except owners' equity (AR2025: S$22.219m).
FY2022 NAV per share: is derived: S$22.219m divided by 206.75m shares.
FY2024 short-term borrowings: include S$7.8m reclassified from non-current because of a covenant breach. Lease and borrowing classifications at 30 Jun 2024 follow the FY2024 announcement; finance leases of S$0.7m were inside borrowings at that date.
FY2024 goodwill and intangibles: use the restated S$6.47m. The originally reported figure was S$5.48m.
Goodwill: of S$5.19m is unchanged throughout. It is split between the My Family Clinic CGUs (S$2.61m) and Jaga-Me (S$2.58m).
Commentary on the balance sheet. Total assets doubled between FY2022 and FY2026, but almost all of the growth is receivables (+S$40.8m) matched by payables (+S$39.1m). These are the gross claim flows of the managed-care business, in which the group pays panel providers and recovers from insurers and corporates. This inflates the balance sheet and depresses asset-turnover ratios without indicating extra economic capital at risk. Credit risk, however, is real: payers' ability and timing to settle now underpin a S$52.5m receivable book, roughly 1.9 times group equity.
Excluding leases, the group has been net cash in every year. Including leases, it moved briefly into net debt in FY2024–FY2025. The FY2026 rebound in cash (+S$4.8m) came from strong operating cash flow and a refinancing in which S$7.6m of new loans were drawn and S$6.3m repaid.
Bank borrowings of S$11.0m at 30 June 2026 are mostly secured. S$8.2m is secured by a legal mortgage over the Bukit Batok head-office leasehold, a charge over shares of a subsidiary, a charge over certain financed receivables and a corporate guarantee (FY2026 results, Note 14).
Cash flow
Notes:
FY2022 figures: are from S&P.
FY2024 capex: follows the FY2025 comparative presentation (PPE S$2.43m plus intangibles S$0.99m). The original FY2024 announcement showed PPE purchases of S$4.23m, which combined both.
FY2023 capex: includes a S$0.54m advance payment for equipment.
FY2026 acquisitions: is the Jaga-Me minority buy-out. The S$1.0m Jaga-Me subscription was intra-group.
Commentary on cash flow. Operating cash flow has been positive every year, but it is volatile because of managed-care working capital. In FY2023, receivables absorbed S$10.5m and OCF fell to S$2.5m. In FY2026, payables growth (+S$7.7m) more than offset receivables growth (−S$7.1m) and OCF reached a five-year high of S$10.5m. On a lease-adjusted basis, free cash flow was negative in FY2023–FY2024. It turned clearly positive in FY2026 (S$4.8m), roughly 4.5 times the proposed S$1.08m dividend.
Return, leverage and efficiency ratios
How these were calculated:
- All ratios are analyst calculations.
FY2022 ROA and asset turnover: use year-end assets because FY2021 total assets were not obtained.
ROIC: uses NOPAT equal to EBIT × (1 − 17%, Singapore's headline rate). Invested capital is total equity plus debt including leases, minus cash.
FY2022 interest coverage: uses S&P interest expense of S$0.23m.
Cash conversion cycle. This is not meaningful for this business and is not disclosed. The receivable and payable balances are dominated by pass-through medical claims, not trade credit on own sales. On a revenue basis, payable days have consistently exceeded receivable days by about 15–35 days. That supports the reading that the group runs a modestly negative claims-float cycle.
Commentary on ratios. FY2026 ROE of about 14% is the best since FY2022 and roughly matches the post-COVID-windfall level. Interest coverage recovered from a stressed 1.2x in FY2024, the year of the covenant breach, to 7.1x. The deterioration in asset turnover is a gross-up effect of claims receivables, not a sign of capital inefficiency.
Half-year profile: notes and sources
Sources: FY2025 and FY2026 results, Note 4.2; HY2026 results. The 2H2026 profit attributable figure is S$2,090,251.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (SGD Mn) | 54.76 | 58.00 | 67.98 | 77.11 | 87.35 |
Revenue growth YoY (%) | 18.0 | 5.9 | 17.2 | 13.4 | 13.3 |
EBITDA company definition (SGD Mn) | 8.04 | 5.46 | 5.04 | 6.74 | 9.54 |
Operating income EBIT derived (SGD Mn) | 5.24 | 2.66 | 1.03 | 2.04 | 4.35 |
Profit before tax (SGD Mn) | 5.00 | 2.16 | 0.02 | 1.17 | 3.82 |
Net profit total (SGD Mn) | 4.30 | 2.01 | 0.35 | 1.10 | 3.48 |
Net profit attributable to owners (SGD Mn) | 3.11 | 2.09 | 0.72 | 1.52 | 3.61 |
EPS basic and diluted (S cents) | 1.51 | 1.02 | 0.35 | 0.74 | 1.75 |
Dividend per share declared for FY (S cents) | 0.45 | 0.30 | 0.00 | 0.10 | 0.52 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 14.68 | 9.42 | 7.42 | 8.75 | 10.92 |
EBIT margin (%) | 9.57 | 4.58 | 1.52 | 2.65 | 4.98 |
PBT margin (%) | 9.13 | 3.72 | 0.03 | 1.52 | 4.37 |
Net margin attributable (%) | 5.68 | 3.60 | 1.06 | 1.98 | 4.14 |
Cost line
| Cost line | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Consumables and medical supplies (SGD Mn) | 18.26 | 19.75 | 19.90 | 20.01 |
Employee benefits expense (SGD Mn) | 31.33 | 38.45 | 43.95 | 50.87 |
Depreciation and amortisation (SGD Mn) | 2.81 | 4.01 | 4.70 | 5.19 |
Other expenses (SGD Mn) | 4.10 | 5.85 | 6.87 | 7.29 |
Finance costs (SGD Mn) | 0.42 | 0.87 | 0.87 | 0.62 |
Employee benefits as % of revenue (%) | 54.0 | 56.6 | 57.0 | 58.2 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (SGD Mn) | 51.63 | 64.95 | 82.90 | 91.07 | 102.79 |
Cash and cash equivalents (SGD Mn) | 20.71 | 19.55 | 18.65 | 16.40 | 21.16 |
Trade and other receivables current (SGD Mn) | 11.66 | 22.11 | 34.02 | 44.99 | 52.49 |
Inventories (SGD Mn) | 2.42 | 3.20 | 3.60 | 4.07 | 3.74 |
Goodwill and intangibles (SGD Mn) | 6.14 | 5.60 | 6.47 | 7.22 | 7.93 |
Borrowings short-term (SGD Mn) | 1.56 | 2.24 | 12.32 | 4.33 | 6.37 |
Borrowings long-term (SGD Mn) | 4.40 | 7.26 | 1.28 | 6.51 | 4.91 |
Lease liabilities total (SGD Mn) | 2.67 | 4.29 | 7.22 | 7.00 | 6.69 |
Total debt incl. leases (SGD Mn) | 8.63 | 13.79 | 20.82 | 17.84 | 17.98 |
Net cash incl. leases (SGD Mn) | 12.08 | 5.76 | -2.17 | -1.44 | 3.18 |
Net cash excl. leases (SGD Mn) | 14.75 | 10.05 | 5.05 | 5.56 | 9.88 |
Trade and other payables (SGD Mn) | 16.76 | 26.32 | 38.25 | 48.16 | 55.85 |
Equity attributable to owners (SGD Mn) | 22.22 | 22.81 | 22.74 | 24.37 | 27.41 |
Total equity incl. NCI (SGD Mn) | 23.91 | 23.75 | 23.01 | 24.06 | 27.94 |
Working capital (SGD Mn) | 13.55 | 14.85 | 3.41 | 10.01 | 12.00 |
NAV per share (S cents) | 10.75 | 11.09 | 11.04 | 11.81 | 13.25 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (SGD Mn) | 9.82 | 2.47 | 4.47 | 5.75 | 10.48 |
Capex PPE plus capitalised software (SGD Mn) | 0.42 | 2.30 | 3.42 | 1.63 | 2.15 |
Free cash flow OCF less capex (SGD Mn) | 9.40 | 0.17 | 1.05 | 4.12 | 8.33 |
Lease payments principal and interest (SGD Mn) | 1.54 | 1.96 | 2.81 | 3.29 | 3.56 |
FCF after lease payments (SGD Mn) | 7.86 | -1.79 | -1.76 | 0.83 | 4.77 |
Dividends paid to shareholders (SGD Mn) | 0.48 | 0.93 | 0.62 | 0.00 | 0.21 |
Share buybacks (SGD Mn) | 0.20 | 0.17 | 0.00 | 0.00 | 0.14 |
Acquisitions incl. NCI buy-outs (SGD Mn) | 0.72 | 0.80 | 0.53 | 0.00 | 0.07 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average owners' equity (%) | 14.82 | 9.29 | 3.16 | 6.47 | 13.95 |
ROA on average total assets (%) | 8.33 | 3.45 | 0.47 | 1.26 | 3.59 |
ROIC NOPAT on invested capital (%) | 36.70 | 12.26 | 3.41 | 6.65 | 14.59 |
Current ratio (x) | 1.61 | 1.47 | 1.06 | 1.18 | 1.18 |
Debt incl. leases to equity (x) | 0.36 | 0.58 | 0.90 | 0.74 | 0.64 |
Net debt to EBITDA, negative means net cash (x) | -1.50 | -1.05 | 0.43 | 0.21 | -0.33 |
Interest coverage EBIT to finance costs (x) | 22.80 | 6.32 | 1.18 | 2.34 | 7.08 |
Asset turnover (x) | 1.06 | 1.00 | 0.92 | 0.89 | 0.90 |
Receivable days on revenue (days) | 78 | 139 | 183 | 213 | 219 |
Payable days on revenue (days) | 112 | 166 | 205 | 228 | 233 |
Income Statement
| Metric | 1HFY2025 | 2HFY2025 | 1HFY2026 | 2HFY2026 |
|---|---|---|---|---|
Revenue half-year (SGD Mn) | 37.93 | 39.18 | 42.33 | 45.03 |
Profit after tax half-year (SGD Mn) | 0.07 | 1.02 | 1.31 | 2.17 |
Profit attributable to owners half-year (SGD Mn) | 0.29 | 1.23 | 1.52 | 2.09 |
Revenue by Region and Revenue by Region (%)
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Singapore revenue (SGD Mn) | 54.29 | 65.30 | 74.99 | 85.59 |
Others Europe and Asia Pacific revenue (SGD Mn) | 3.72 | 2.68 | 2.12 | 1.76 |
Singapore share of revenue (%) | 93.6 | 96.0 | 97.2 | 98.0 |
Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Singapore revenue growth (%) | 20.3 | 14.8 | 14.1 |
Others revenue growth (%) | -27.8 | -20.9 | -16.9 |
Segment Overview
| Segment | Singapore | Others |
|---|---|---|
GP clinic services (SGD Mn) | 20.10 | 0.00 |
Specialist care services (SGD Mn) | 19.83 | 0.00 |
Managed healthcare solutions (SGD Mn) | 22.14 | 0.01 |
Pharmaceutical services (SGD Mn) | 12.79 | 1.76 |
Mobile and digital health services (SGD Mn) | 7.90 | 0.00 |
Others (SGD Mn) | 2.84 | 0.00 |
Share Price History
| Date | Price (SGD) | Source |
|---|---|---|
31 May 2019 (IPO) | 0.200 | Offer document / The Edge |
7 Jan 2025 | Up to 0.120 (insider purchase price) | Simply Wall St insider record |
7 Jul 2026 | 0.158 (52-week range 0.088–0.164) | FSMOne |
24 Jul 2026 | 0.158 (52-week change +37.4%) | StockAnalysis |
11 Sep 2026 | 0.188 | StockAnalysis |
8 Oct 2026 | 0.180 | StockAnalysis |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalisation (SGD Mn) | 37.2 | 206.87m shares |
Enterprise value incl. leases (SGD Mn) | 34.1 | Market cap + S$17.98m debt and leases − S$21.16m cash; excludes S$0.52m NCI |
P/E (x) | 10.3 | FY2026 basic EPS 1.75 cents |
EV/EBITDA (x) | 3.6 | FY2026 EBITDA S$9.54m (pre-lease) |
EV/Sales (x) | 0.39 | FY2026 revenue |
P/B (x) | 1.36 | NAV 13.25 cents |
Dividend yield (%) | 2.9 | 0.52 cents proposed |
FCF yield after leases (%) | 12.8 | S$4.77m / S$37.2m |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Dividend per share (S cents) | 0.23 | 0.45 | 0.30 | 0.00 | 0.10 | 0.52 |
Payout ratio of PATMI (%) | 31.0 | 29.9 | 30.0 | 0.0 | 13.5 | 29.8 |
Capital Markets
| Item | Detail |
|---|---|
Share purchase mandate | Renewed at AGMs; the 2025 appendix letter covers it |
FY2023 purchases | 1,000,000 shares for S$173,960 |
FY2026 purchases | 950,200 shares for S$144,029 |
Treasury shares at 30 Jun 2026 | 1,014,165 |
Moody's / S&P / Fitch ratings | None (unrated) |
Borrowings due within 1 year (30 Jun 2026) | S$6.37m (secured S$4.01m; unsecured S$2.36m) |
Borrowings due after 1 year (30 Jun 2026) | S$4.91m (secured S$4.16m; unsecured S$0.75m) |
Lease liabilities | Current S$3.17m; non-current S$3.52m |
Loans from related parties | About S$0.3m (down from S$1.0m) |
Analyst Conclusions
Management guidance (FY2026 commentary, 26 Aug 2026)
Management gives no numerical guidance. Its qualitative outlook is:
-
Continued pressure from rising healthcare costs, which supports demand for Alliance Medinet's cost-managed care.
-
Commitment to Jaga-Me's growth after taking ownership to 98.4%.
-
Pursuit of more institutional health-IT work after YHCMS.
-
Rising contributions expected from the two new specialist clinics.
-
Margin pressure from manpower and operating costs, offset by AI and technology investment.
-
Macro uncertainty.
-
A focus on portfolio optimisation, including rationalising or repositioning businesses.
Consensus growth expectations: not available (no coverage).
Bull case
-
Earnings quality is improving structurally. PBT rose to S$3.82m in FY2026, with managed care (S$3.25m) and a near-breakeven mobile and digital segment doing the work. Removing Evoque's FY2026 operating loss of about S$1.1m alone would add about 30% to FY2026 PBT in FY2027, before any growth.
-
Mispriced cash generation. At about S$34m EV, the stock trades at 3.6x pre-lease EBITDA, and FCF after leases (S$4.8m) gives a yield of about 13%. Net cash excluding leases is S$9.9m, about 27% of market cap.
-
Option value in home care. With 98.4% of Jaga-Me and MIC@Home now a mainstream service across five restructured hospitals, any national scale-up of hospital-at-home accrues almost entirely to AHG. The FY2026 subscription price (S$0.1525 per share) gives an inexpensive base.
Bear case
-
Specialist attrition will cut FY2027 revenue. Two colorectal practices left on 1 Jul 2026, and Evoque closed. Specialist revenue (S$19.8m in FY2026) will lose these contributors, which are not separately quantified, and the new clinics must replace them.
-
Working-capital and credit exposure is disproportionate to equity. Receivables of S$52.5m against equity of S$27.9m mean a single payer dispute or delay could absorb a year's profit. The FY2024 covenant breach shows how thin the buffer is.
-
Governance and liquidity discounts persist. The founder controls about 68%, the free float is about 14%, there is no analyst coverage, the Chair and CEO roles are combined, and related-party professional fees are S$6.1m. Re-rating catalysts are scarce, and a 10% one-day fall (8 Oct 2026) shows how volatile the stock can be.
Catalysts and monitorables (next 12 months)
| Timing | Item |
|---|---|
| 27 Oct 2026 | AGM; approval of the 0.52-cent dividend (payable 13 Nov 2026) |
| Oct 2026 | Annual Report 2026: audited FY2026 numbers (to confirm the unaudited figures), FY2026 headcount, shareholder statistics, remuneration bands |
| Feb 2027 | HY2027 results: first half without colorectal or Evoque; specialist segment run-rate |
| Ongoing | Mobile and digital: whether positive EBITDA holds and becomes positive PBT |
| Ongoing | Managed care: receivable days (219 in FY2026) and segment margin (14.7%) |
| Ongoing | New institutional IT contracts after YHCMS |
| Ongoing | Any further portfolio rationalisation, or new specialist recruitment |
| 2028 horizon | Board refresh: all three independent directors reach nine years' tenure in early 2028 |
Analyst verdict
Alliance Healthcare Group exits FY2026 as a better business than its five-year share-price record suggests. The post-COVID reset of FY2023–FY2024 has given way to a cleaner earnings mix. Alliance Medinet's managed-care franchise is now the dominant profit pool. The home-care arm has reached EBITDA breakeven. Management has shown, for the first time, a willingness to close loss-making ventures rather than fund them indefinitely. FY2026 delivered the strongest operating cash flow in the company's listed history (S$10.5m), a lease-adjusted FCF yield in the low teens at S$0.18, ROE near 14% and a dividend payout restored to about 30%.
These positives are offset by real structural limits. The group is a Singapore-only micro-cap whose specialist revenue depends on contracted doctors who can and do leave. Its claims-driven balance sheet carries receivables nearly twice its equity. Its cost base is dominated by labour costs that are rising faster than revenue. Disclosure is adequate for a Catalist issuer but thin on client concentration, payer terms and segment KPIs, and the FY2026 numbers remain unaudited until the annual report is published.
On balance, the valuation (about 10x trailing P/E and 3.6x EV/EBITDA) already prices in a substantial discount for illiquidity and founder control. The risk-reward therefore depends on whether FY2027 can hold FY2026 earnings after the specialist exits. If the Evoque loss removal and managed-care growth offset the colorectal departures, the earnings base of about S$3.5m looks sustainable, and the stock should be judged on dividend and cash yield rather than multiple expansion. If specialist attrition spreads or claims receivables deteriorate, the thin capital buffer leaves little room for error.
Assessment: fundamentally improving, but with high company-specific risk. The HY2027 results (February 2027) are the key test of earnings durability.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background and education (AR2025) | Committee roles |
|---|---|---|---|---|
Dr Barry Thng Lip Mong | Executive Chairman and CEO; founder | 6 Jun 2006 | MBBS (NUS, 1991); MMed (Family Medicine) (NUS, 1998); Fellow, College of Family Physicians Singapore (2002) and Academy of Medicine Singapore (2014) | Leads the executive Sustainability Committee |
Dr Mok Kan Hwei, Paul | Executive Director; Head of Specialist Care Services; Medical Director, My ENT Specialist | 28 Mar 2019 | MBBS (NUS, 1991); Diploma of Fellowship, Royal College of Physicians and Surgeons of Glasgow (1997); committee member, Otorhinolaryngology Residency Advisory Committee | — |
Mr Wong Hin Sun, Eugene | Lead Independent Director | 28 Mar 2019 | Founder and MD, Sirius Venture Capital (since 2002); Chairman, Tangram Asia Capital; non-executive Deputy Chairman, NTUC LearningHub; non-executive Vice-Chairman, Japan Foods Holding; Deputy non-executive Chairman, Jason Marine Group; Lead ID, APAC Realty; board of Singapore Cruise Centre. BBA (1st class, NUS); MBA (Imperial College); Harvard OPM; CFA | Chairman, ARMC; member, NC and RC |
Mr Lim Heng Chong Benny | Independent Director | 28 Mar 2019 | Partner, Chris Chong & C T Ho LLP; nearly 30 years in practice (funds, financial regulation, M&A). LLB and LLM (NUS) | Chairman, NC; member, ARMC and RC |
Dr Leong Peng Kheong Adrian Francis | Independent Director | 27 Feb 2019 | More than 40 years in medicine; former Chief of Surgery and Vice Chairman of the Medical Board at NUH; former elected member of the Singapore Medical Council. MBBS (NUS, 1983); MMed (Surgery) (1988) | Chairman, RC; member, ARMC and NC |
Executive Leadership Team
| Name | Title | With group since | Background (AR2025) |
|---|---|---|---|
Ms Karen Ji Cuihua | Chief Financial Officer | Aug 2021 | Deloitte & Touche; Ministry of Health internal audit; CFO roles at other SGX-listed companies. BSc (1st class) Applied Accounting, Oxford Brookes; ISCA member |
Ms Jenny Oh | Chief Operating Officer | Jan 2019 | Senior management roles at insurers. Bachelor of Business, Monash |
Ms Ong Kai Koon, Karen | Head of Managed Healthcare Solutions; EVP, Alliance Medinet | 2017 | Corporate solutions provider management. Diploma in Marketing Management; health insurance certificate |
Mr Wong Chien Yeh | Head of Pharmaceutical Services | 2008 | Registered pharmacist. BSc (Pharmacy), NUS |
Ms Chiang Wai Ming | Company Secretary | — | ACIS |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Status |
|---|---|
Board size | 5 |
Independent directors | 3 of 5 (60%) |
Chair / CEO | Combined (Dr Thng). Mitigated by a Lead Independent Director (Mr Wong) |
Committees | Audit and Risk Management (all independent); Nominating; Remuneration (all independent) |
Women on board | 0 of 5 |
Independent director tenure | All three independents appointed Feb–Mar 2019, about 7.6 years by Oct 2026 |
Sustainability governance | Board oversight, with an executive Sustainability Committee led by the CEO and supported by the COO and CFO. All directors completed approved sustainability training |
Interested-person transactions | No IPT mandate. No IPT of S$100,000 or more in FY2025 or FY2026 |
Major Shareholders
| Holder | Shares (m) | Stake (%) | Notes |
|---|---|---|---|
Alpine Investment Holdings Pte Ltd | 133.45 | 64.51 | Holding vehicle in which Dr Thng is reported to have a deemed interest (The Edge, Oct 2021) |
Dr Barry Thng Lip Mong (direct) | 8.58 | 4.15 | Combined direct and deemed interest about 68.3% (The Edge, Oct 2021) |
28 Holdings Pte Ltd | 8.00 | 3.87 | Classified as an institution by Simply Wall St |
Dr Mok Kan Hwei, Paul | 7.14 | 3.45 | Bought 538,710 shares at up to S$0.12 on 7 Jan 2025 |
Lim Fong | 7.13 | 3.45 | Individual |
Wong Chien Yeh | 6.63 | 3.21 | Head of Pharmaceutical Services |
Yun Kok Onn | 2.46 | 1.19 | Individual |
Ang Hao Yao | 1.70 | 0.82 | Individual |
Competitive Landscape
Key Competitors
| Competitor | Segment(s) overlapping | Latest revenue | Relative positioning |
|---|---|---|---|
Raffles Medical Group (SGX: BSL) | GP, specialist, corporate health, insurance | S$765.3m FY2025 (Dec YE) | Integrated hospital plus clinic plus insurer; about 9 times AHG's revenue; net-cash balance sheet |
Q&M Dental Group (SGX: QC7) | Primary-care clinic chains (dental) | S$197.2m FY2025 | Larger clinic roll-up; capital-markets funded (S$130m debt issuance in 2025) |
Thomson Medical Group (SGX: A50) | Specialist / private hospital | S$215.9m 1H2026 revenue; net loss S$10.2m | Hospital-anchored specialist platform |
AsiaMedic (SGX Catalist) | Health screening, imaging | S$35.2m FY2025; PATMI S$2.0m | Competes with Alliance Medical Centre and Alliance Radiology |
Livingstone Health (SGX Catalist) | GP and specialist clinics | S$27.6m FY2025; net profit attributable about S$0.56m | Comparable-scale multidisciplinary group (20 clinics) |
Singapore Paincare Holdings (SGX Catalist) | Specialist, GP | S$26.0m FY2025 (Jun YE); loss S$4.0m | Peer in specialist roll-ups; impairment-hit |
Fullerton Health (private) | Corporate health, TPA, clinics | — | Major regional corporate-health competitor |
MHC Asia Group (private) | Medical TPA | — | Direct competitor of Alliance Medinet |
Integrated Health Plans (IHP, private) | Medical TPA | — | Direct competitor of Alliance Medinet |
Parkway / IHH Healthcare (Parkway Shenton) | GP clinics, screening, corporate health | — | Scale incumbent |
Speedoc, Homage (private) | Home medical and home care | — | Direct competitors of Jaga-Me |
Zuellig Pharma, DKSH | Pharmaceutical distribution | — | Far larger distributors; AHG is a niche wholesaler |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | AHG FY2026 | Raffles Medical FY2025 | Q&M Dental FY2025 | Livingstone Health FY2025 |
|---|---|---|---|---|
Revenue (SGD Mn) | 87.35 | 765.30 | 197.20 | 27.60 |
Revenue growth (%) | 13.3 | 1.8 | 9.2 | 9.0 |
Net profit attributable (SGD Mn) | 3.61 | 70.57 | 9.30 | 0.56 |
Net margin attributable (%) | 4.1 | 9.2 | 4.7 | 2.0 |



